Boehringer Ingelheim is a German pharmaceutical company that is recognized for Innovation and Research and Development in the 2022 Clinical Trials Arena Excellence Awards.
Like most of their competitors, the German multinational has been developing a COVID-19 treatment. The drug has shown a favourable safety and efficacy profile in an open-label Phase II trial and the company has announced that the drug is entering its Phase III trial. The compound has proved particularly effective in treating COVID-19 patients suffering from acute respiratory distress syndrome.
Go deeper with GlobalData
Also in Phase III of its development is the company’s heart failure treatment. The compound is being developed in collaboration with Eli Lilly and results show that it substantially lowers the risk of death or hospitalisation from heart failure in adults with heart failure with preserved ejection fraction.
In collaboration with Amgen the company is also developing a potential combination therapy for cancer. It consists of SOS1::pan-KRAS inhibitor BI 1701963 and Lumakras (sotorasib) and is aimed at patients with lung and colorectal cancers.
The German multinational is also in the process of developing neurological and dermatological treatments.
Company Profile
Boehringer Ingelheim is a manufacturer, marketer, and supplier of pharmaceutical products. The product portfolio of the company includes Giotrif, Jardiance, OFEV, Pradaxa, Praxbind, Spiolto, Spiriva, and Vargatef among others. It also offers prescription medicines in the areas of metabolic diseases such as diabetes, oncology, central nervous system diseases, which include schizophrenia, Alzheimer’s disease, Parkinson’s disease, and restless legs syndrome.
Additionally, the company is also engaged in contract manufacturing, research, and clinical trial activities. Boehringer Sohn also develops medicines for animal health.
The company’s operations are spread across Africa, Asia, Europe, North America, and South America. Boehringer Sohn is headquartered in Ingelheim, Germany.
